胰高血糖素样肽-1类似物对减重影响

Effects of glucagon-like peptide-1 receptor on weight loss

随着发病率逐年增加,肥胖已成为全球公共健康问题。它不仅是一种多因素的慢性代谢性疾病,也是2型糖尿病、冠心病、高脂血症、肿瘤等多种疾病的危险因素。肥胖的发病机制复杂,与遗传、环境、氧化应激、肠道菌群及胰岛素抵抗密切相关。诊治肥胖,刻不容缓。胰高血糖素样肽-1(GLP-1)类似物是一种新型减重药物,既可保护B细胞功能、改善胰岛素抵抗,也可增加饱腹感、延缓胃排空、减少脂肪堆积,达到减肥目的。本文就肥胖发病现状、发病机制及GLP-1类似物对减重的影响进行综述。

With the increasing incidence year by year, obesity has become a global public health problem.It is not only a kind of chronic metabolic disease, but also the risk factors of type 2 diabetes mellitus, coronary heart disease, hyperlipidemia, tumor and so on.The pathogenesis of obesity is complex, which is closely related to heredity, environmental factors, oxidative stress, gut microbiota and insulin resistance.Making a diagnosis and giving treatment on obesity are urgently needed.GLP-1 receptor is a new type of weight loss drug, which not only can protect the function of β cell and improve insulin resistance, but also can increase the sense of fullness, delay gastric emptying and reduce fat accumulation, achieving the purposes of weight loss. This article summarized the present situation and pathogenesis of obesity and the effects ofglucagon-like peptide- 1 receptor on weight loss.